Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab

Background & Aims: Atezolizumab + bevacizumab and durvalumab + tremelimumab are the standard first-line therapies for advanced hepatocellular carcinoma (HCC). Histological variables routinely associated with outcomes remain poorly described. We aimed to assess the prognostic and predictive value...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Alexandre Sayadi, Claudia Campani, Astrid Laurent-Bellue, Marianne Ziol, Luca Di Tommaso, Etienne Becht, Benoit Terris, Julien Calderaro, Luca Messerini, Miguel Albuquerque, Federico Lipsich, Carolina Gutierrez, Marion Dhooge, Lisa Lellouche, Giuliana Amaddeo, Alina Pascale, Olivier Rosmorduc, Fabio Marra, Lorenza Rimassa, Marco Dioguardi Burgio, Jean-Charles Nault, Mohamed Bouattour, Valérie Paradis, Aurélie Beaufrère
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-07-01
coleção:	JHEP Reports
Assuntos:	Vessels encapsulating tumor clusters Hepatocellular carcinoma Atezolizumab Bevacizumab Histology Response
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S258955592600145X
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!